^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | zoledronic acid (Bone resorption factor inhibitor, Osteoclast inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer
Published date:
02/16/2021
Excerpt:
However, ER+/HER2- patients younger than age 45 who were treated with ZOL had significantly worse TTR and TTNBR with a trend towards worse TTBR, BCS and OS.
DOI:
10.1007/s10549-021-06100-2
Trial ID:
